Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 okt 2006 - 18:02
Statutaire naam
Pharming Group N.V.
Titel
PHARMING‘S EXTRAORDINARY MEETING OF SHAREHOLDERS TO BE HELD IN LEIDEN ON NOVEMBER 1, 2006
Bericht
Leiden, The Netherlands, October 12, 2006. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) announced today that the Company’s next Extraordinary Meeting of shareholders will be held at the Holiday Inn in Leiden on November 1, 2006 commencing at 11.00 am CET. Purpose of the meeting is to vote on the proposal to appoint Dr. Bruno Giannetti as a member of the Board of Management in the position of Chief Operations Officer.
Dr. Giannetti (54) has more than 25 years experience in the pharmaceutical and biotech industry. He was Head of Clinical Research at Madaus, Germany and world-wide Vice-President Marketing and Medical Information at Immuno, Austria. He served as senior management consultant for pharmaceutical R&D projects at Coopers & Lybrand, Switzerland and UK and as Chief Operations Officer and subsequently President and CEO of Verigen AG, Germany. He is currently the CEO of AM-Pharma, The Netherlands.
Dr. Giannetti is the founder of CRM, a well established European Clinical Research Organization specialized in international pharmaceutical clinical research. He is a visiting lecturer at the University of Bonn and former President of the Biotech Group of the German Bio Pharmaceutical Industry Organization. He is also accredited as Qualified Person (relevant for the manufacturing of pharmaceutical products). He holds a PhD in chemistry and a MD PhD degree in medicine from the University of Bonn.
All documentation relating to this meeting will be available on Pharming’s website as of October 17, 2006.
Background on Pharming Group NV
Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notif
Datum laatste update: 07 oktober 2024